Guardant Health

Guardant Health PP&E per Employee

The PP&E per Employee of Guardant Health (GH) as of Nov 1, 2026 is 67,437.75 USD. In the previous year, PP&E per Employee was 126,065.86 USD — a change of -46.51% (lower).

PP&E per Employee

67,437.75USD

YoY

-46.51%

Last updated:

PP&E per Employee of Guardant Health is 2022 67,437.75 USD. PP&E per Employee of Guardant Health was 2021 126,065.86 USD. It decreases by -46.51% lower compared to the previous year.

The Guardant Health PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2016
5,073.90 USD
Jan 1, 2017
6,440.16 USD
Jan 1, 2018
12,451.00 USD
Jan 1, 2019
29,240.16 USD
Jan 1, 2020
25,213.65 USD
Jan 1, 2021
126,065.86 USD
Jan 1, 2022
67,437.75 USD
The Guardant Health PP&E per Employee history
YEARPP&E per EmployeeYoY
67,437.75USD-46.51%
126,065.86USD+399.99%
25,213.65USD-13.77%
29,240.16USD+134.84%
12,451.00USD+93.33%
6,440.16USD+26.93%
5,073.90USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guardant Health Stock analysis

What does Guardant Health do? Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guardant Health stock

PP&E per Employee of Guardant Health is 67,437.75 USD in 2022.

PP&E per Employee of Guardant Health changed from 126,065.86 USD to 67,437.75 USD, representing a -46.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Guardant Health since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Guardant Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Guardant Health

All Key Metrics — Guardant Health